Recent Advances in Immune Checkpoint Inhibition and Antibody Drug Conjugates in Urothelial Carcinoma

Dear Colleagues,

This Special Issue highlights recent advances in immune checkpoint inhibition and antibody drug conjugates for the treatment of urothelial carcinoma, focusing on the latest research and clinical developments in this area. It explores the role of immune checkpoint inhibitors and antibody drug conjugates in improving outcomes for patients with urothelial cancer, a disease historically characterized by poor prognosis in advanced stages. This Special Issue covers novel therapeutic combinations of immune checkpoint inhibitors and antibody drug conjugates as well as their combinations with chemotherapy, targeted therapies, and other immunotherapies aimed at enhancing treatment efficacy. It also addresses biomarkers for patient selection, resistance mechanisms, and strategies to overcome immune evasion. Furthermore, this Special Issue discusses the impact of immune checkpoint inhibition and antibody drug conjugates on overall survival, progression-free survival, and quality of life, with a focus on optimizing treatment regimens. By examining both the challenges and successes of these therapies in urothelial carcinoma, this Special Issue provides a comprehensive overview of the current landscape and future directions in this rapidly evolving field of bladder cancer treatment.

Dr. Qian Janie Qin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.